Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
基本信息
- 批准号:8240106
- 负责人:
- 金额:$ 40.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAffinityAntibody FormationAntigen-Presenting CellsAntigensArthritisAutoimmune DiseasesAutoimmunityBiological ModelsCD4 Positive T LymphocytesCell CountCell physiologyCellsCellular biologyDataDevelopmentDiagnosisDiagnosticEnvironmentFailureFrequenciesGoalsHealthHemagglutininIL2RA geneImmuneImmune responseImmune systemImmunityIn VitroInfectionInflammatoryMusPeptidesPlayProcessPublic HealthRegulationRegulatory T-LymphocyteRheumatoid ArthritisRoleShapesSignal TransductionSpecificityT-Cell ReceptorT-LymphocyteTherapeuticTissuesTransgenesTransgenic MiceVariantViralVirusautoimmune arthritiscancer transplantationhuman diseasein vivoinfluenzavirusinsightneuronal cell bodynovelpathogenpreventpromoterresponsethymocyte
项目摘要
DESCRIPTION (provided by applicant): This project's goal is to use a well-characterized model system to define processes governing the formation and activity of CD4+CD25+Foxp3+ regulatory T (Treg) cells. The proposal will make use of existing lineages of transgenic mice expressing the influenza virus hemagglutinin (HA) under the control of a variety of promoters (HA Tg mice) and/or HA-specific T cell receptors with varying affinities and specificities for the HA (TCR Tg mice). By analyzing double transgenic mice co-expressing HA-specific TCRs and neo-self HA peptides (TCRxHA Tg mice), we have shown that highly specific interactions with HA-derived peptides can induce thymocytes to undergo selection to become Treg cells that suppress conventional CD4+ T (Tconv) cell responses in vitro, and can modify immune responses in vivo. We have shown that the formation of these Treg cells is highly sensitive to variations in the amount of the HA that is expressed in different HA Tg lineages, and that expression of HA selectively by antigen presenting cells in one of these lineages (designated HACII mice) induces the spontaneous development of inflammatory arthritis in TCRxHACII mice despite the presence of antigen-specific Treg cells. We will use this unique model system to examine how TCR specificity directs Treg cell formation and determines the capacity of Treg cells to modulate anti-self and anti-viral immune responses. In Aim 1 we will examine how TCR recognition of self-peptides shapes Treg repertoire formation. We will modulate the reactivity of the TCR for self-peptides and determine the effects on thymic Treg cell development in TCRxHA Tg mice, and will use adoptive transfer approaches to examine the development of Treg cells in the periphery of HA Tg mice under various conditions. In Aim 2 we will examine how Treg specificity for self-peptides shapes anti-viral immunity. We will analyze the ability of Treg cells from TCRxHA Tg mice to modulate antibody responses to influenza viruses with which they possess varying degrees of crossreactivity, and examine HA Tg mice that do not co-express TCR transgenes for their frequencies of virus- specific CD4+ Treg and Tconv cells. In Aim 3 we will determine how TCR specificity impacts the ability of Treg cells to prevent autoimmune arthritis. We will either deplete Treg cells, or add Treg cells with varying degrees of reactivity with the HA to pre-arthritic TCRxHACII mice, and determine the effects on cellular processes that accompany arthritis development. We will also analyze the expansion and differentiation of Treg cells with varying degrees of reactivity for the HA following transfer into HACII or TS1xHACII mice. These studies will provide fundamental insights into the mechanisms of immune repertoire formation and tolerance. They will enhance our understanding of the role immune regulation plays in anti-viral immunity and how its failure can contribute to autoimmunity, and will enhance the ability of Treg cells to b exploit in diagnostic therapeutic settings.
PUBLIC HEALTH RELEVANCE: Regulatory T cells play an vital role in preventing the immune system from mounting harmful responses to the body's cells and tissues, such as can occur in autoimmune diseases. These cells can also modify the activity of the immune system in settings such as infection, transplantation and cancer. This proposal uses genetically-modified mice to analyze mechanisms and cellular processes than govern the development and activity of regulatory T cells, and to develop novel insights into regulatory T cell biology that will facilitate their application for diagnosis and therapy of human diseases.
描述(由申请人提供):本项目的目标是使用充分表征的模型系统来定义控制CD 4 + CD 25 + Foxp 3+调节性T(Treg)细胞形成和活性的过程。该提案将利用现有的转基因小鼠谱系,这些转基因小鼠在多种启动子(HA Tg小鼠)和/或对HA具有不同亲和力和特异性的HA特异性T细胞受体(TCR Tg小鼠)的控制下表达流感病毒血凝素(HA)。通过分析共表达HA特异性TCR和新自身HA肽的双转基因小鼠(TCRxHA Tg小鼠),我们已经表明,与HA衍生肽的高度特异性相互作用可以诱导胸腺细胞经历选择,成为抑制体外常规CD 4 + T(Tconv)细胞应答的Treg细胞,并且可以改变体内免疫应答。我们已经表明,这些Treg细胞的形成对在不同HA Tg谱系中表达的HA的量的变化高度敏感,并且尽管存在抗原特异性Treg细胞,但通过这些谱系之一(指定为HACII小鼠)中的抗原呈递细胞选择性地表达HA诱导TCR xHACII小鼠中炎性关节炎的自发发展。我们将使用这种独特的模型系统来研究TCR特异性如何指导Treg细胞的形成,并确定Treg细胞调节抗自身和抗病毒免疫应答的能力。在目标1中,我们将研究TCR对自身肽的识别如何影响Treg库的形成。我们将调节TCR对自身肽的反应性,并确定对TCRxHA Tg小鼠中胸腺Treg细胞发育的影响,并将使用过继转移方法来检查各种条件下HA Tg小鼠外周中Treg细胞的发育。在目标2中,我们将研究Treg对自身肽的特异性如何塑造抗病毒免疫。我们将分析来自TCRxHA Tg小鼠的Treg细胞调节对流感病毒的抗体应答的能力,它们与流感病毒具有不同程度的交叉反应性,并检查不共表达TCR转基因的HA Tg小鼠的病毒特异性CD 4 + Treg和Tconv细胞的频率。在目标3中,我们将确定TCR特异性如何影响Treg细胞预防自身免疫性关节炎的能力。我们将耗尽Treg细胞,或将与HA具有不同程度反应性的Treg细胞添加到关节炎前TCRxHACII小鼠,并确定对伴随关节炎发展的细胞过程的影响。我们还将分析Treg细胞在转移到HACII或TS 1xHACII小鼠中后对HA具有不同程度反应性的扩增和分化。这些研究将为免疫库形成和耐受机制提供基本见解。它们将增强我们对免疫调节在抗病毒免疫中的作用以及其失效如何有助于自身免疫的理解,并将增强Treg细胞在诊断治疗环境中利用B的能力。
公共卫生相关性:调节性T细胞在防止免疫系统对身体细胞和组织产生有害反应方面起着至关重要的作用,例如可能发生在自身免疫性疾病中。这些细胞还可以在感染、移植和癌症等环境中改变免疫系统的活性。该提案使用转基因小鼠来分析机制和细胞过程,而不是管理调节性T细胞的发育和活性,并开发对调节性T细胞生物学的新见解,这将有助于它们在人类疾病诊断和治疗中的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW J CATON其他文献
ANDREW J CATON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW J CATON', 18)}}的其他基金
Regulatory T Cell Activity in Anti-Viral Immunity
抗病毒免疫中的调节性 T 细胞活性
- 批准号:
8089285 - 财政年份:2010
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
7920671 - 财政年份:2009
- 资助金额:
$ 40.99万 - 项目类别:
Regulatory T Cell Activity in Anti-Viral Immunity
抗病毒免疫中的调节性 T 细胞活性
- 批准号:
7746170 - 财政年份:2009
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
6756805 - 财政年份:2004
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
8044711 - 财政年份:2004
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
7663631 - 财政年份:2004
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
7213400 - 财政年份:2004
- 资助金额:
$ 40.99万 - 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
- 批准号:
8436272 - 财政年份:2004
- 资助金额:
$ 40.99万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 40.99万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 40.99万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 40.99万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 40.99万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 40.99万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 40.99万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 40.99万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 40.99万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 40.99万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 40.99万 - 项目类别:














{{item.name}}会员




